Loading company…
Navignostics analyzes tumor proteins and cellular features to support cancer research and treatment decisions.
Founded in 2022 and based in Zurich, Navignostics develops a biotechnology research platform for cancer. Its analysis uses panels of metal-labeled antibodies and imaging mass cytometry to examine tumor proteins, cell types, and cellular interactions. In November 2022, it raised CHF 7.5 million in seed funding led by Bruker Invest AG, with Think.Health Ventures, Ventura BioMed Investors, and Zürcher Kantonalbank Asset Management participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in